- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03822273
Analgesic Effect of Acupuncture for Patients With Rib Fractures
Analgesic Effect of Acupuncture for Patients With Rib Fractures: a Randomized-controlled Trial
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 833
- Kaohsiung Chang Gung Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Chest trauma
- Presence of one or more, unilateral or bilateral rib fractures diagnosed with chest X-ray
- Maximal rib pain score of more than 5 obtained using the numerical rating scale (NRS: 0-10)
- Ability to describe the sites of pain and evaluate the pain intensity accurately
Exclusion Criteria:
- Unable to describe the sites of pain and evaluate the pain intensity accurately
- There are open wounds on the sites of acupuncture points
- Severe multiple trauma or any poorly controlled diseases such as atelectasis, pneumonia, or other infectious diseases, immune system dysfunction, bleeding tendency, psychiatric disorders, and skin problems
- Receive surgical management of rib fractures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Traditional acupuncture (TA)
The subject will receive real acupuncture treatment once per day for 3 days after enrollment.
|
Procedure: real acupuncture. Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min. |
|
Active Comparator: Laser acupuncture (LA)
The subject will receive laser acupuncture treatment once per day for 3 days after enrollment.
|
Procedure: laser acupuncture. Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies [B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz]; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2). |
|
Placebo Comparator: Sham laser acupuncture (SLA)
The subject will receive sham laser acupuncture treatment once per day for 3 days after enrollment.
|
Procedure: sham laser acupuncture. Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of pain relief
Time Frame: The NRS will be assessed at Day 1, Day 2 and DAY 3 pretreatment and posttreatment in the morning (8:00-10:00) and evening (15:00-17:00), respectively. Primary outcome is the change of NRS score on DAY 1 pretreatment and DAY 3 post treatment.
|
Maximal pain intensity (Numerical Rating Scale; NRS: 0-10) evaluated by participants themselves during deep breathing, coughing, and turning over in bed.
|
The NRS will be assessed at Day 1, Day 2 and DAY 3 pretreatment and posttreatment in the morning (8:00-10:00) and evening (15:00-17:00), respectively. Primary outcome is the change of NRS score on DAY 1 pretreatment and DAY 3 post treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sustained maximal inspiration lung volumes
Time Frame: The sustained maximal inspiration lung volumes will be assessed at Day 1, Day 2 and DAY 3 pretreatment and posttreatment in the morning (8:00-10:00) and evening (15:00-17:00), respectively.
|
Sustained maximal inspiration lung volumes
|
The sustained maximal inspiration lung volumes will be assessed at Day 1, Day 2 and DAY 3 pretreatment and posttreatment in the morning (8:00-10:00) and evening (15:00-17:00), respectively.
|
|
Number of cases with pulmonary complications
Time Frame: Follow-up for one month
|
Pulmonary complications including pneumonia, atelectasis, pleural effusion, acute respiratory distress syndrome, and respiratory failure.
|
Follow-up for one month
|
|
Saliva cortisol level
Time Frame: The saliva cortisol level will be assessed at Day 1, Day 2 and DAY 3 pretreatment and posttreatment in the morning (8:00-10:00) and evening (15:00-17:00), respectively.
|
Saliva cortisol level
|
The saliva cortisol level will be assessed at Day 1, Day 2 and DAY 3 pretreatment and posttreatment in the morning (8:00-10:00) and evening (15:00-17:00), respectively.
|
|
Heart rate variation
Time Frame: The heart rate variation will be assessed at Day 1, Day 2 and DAY 3 pretreatment and posttreatment in the morning (8:00-10:00) and evening (15:00-17:00), respectively.
|
Heart rate variation
|
The heart rate variation will be assessed at Day 1, Day 2 and DAY 3 pretreatment and posttreatment in the morning (8:00-10:00) and evening (15:00-17:00), respectively.
|
|
The dose of narcotic and non-narcotic analgesics used
Time Frame: Record the medication use for 2 weeks after participant enrolled
|
Record the use of narcotic and non narcotic analgesics based on chart reviews.
Narcotic drugs include codeine, tramadol, and morphine.
Non narcotic drugs include acetaminophen, ibuprofen, diclofenac, ketoprofen, mefenamic acid, and parecoxib.
|
Record the medication use for 2 weeks after participant enrolled
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chun-Ting Liu, MD, Chang Gung Memorial Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201701455A3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Analgesia
-
University Hospital, CaenNot yet recruitingPostoperative Care | Postoperative Analgesia | Analgesia Assessment | PosthectomyFrance
-
Brigham and Women's HospitalEnrolling by invitationEpidural Analgesia | Learning Curve | Epidural Analgesia for Labour and DeliveryUnited States
-
Dr. John A. Thiel Medical Professional CorporationNot yet recruiting
-
Tanta UniversityRecruiting
-
SSM Health Bone and Joint Hospital at St AnthonyRecruitingAnalgesiaUnited States
-
Makassed General HospitalRecruiting
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Abd-Elazeem Abd-Elhameed ElbakryActive, not recruiting
Clinical Trials on Traditional acupuncture (TA)
-
Cedars-Sinai Medical CenterCompleted
-
University of MichiganMassachusetts General Hospital; National Center for Complementary and Integrative...Completed
-
Brigham and Women's HospitalMassachusetts General Hospital; National Center for Complementary and Integrative...Completed
-
China Academy of Chinese Medical SciencesUnknownImpaired Glucose Tolerance
-
The University of Hong KongNational Center for Complementary and Integrative Health (NCCIH)Unknown
-
Cedars-Sinai Medical CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedCoronary Artery DiseaseUnited States
-
Beijing University of Chinese MedicineXiyuan Hospital of China Academy of Chinese Medical SciencesCompletedChemotherapy-induced Nausea and VomitingChina
-
Beijing University of Chinese MedicineGuang'anmen Hospital of China Academy of Chinese Medical Sciences; Xiyuan Hospital... and other collaboratorsCompletedChemotherapy-induced Nausea and VomitingChina
-
VA Office of Research and DevelopmentAnalydata, IncCompleted
-
Qilu Hospital of Shandong UniversityWeifang Yidu Central Hospital; The People's Hospital of Yinan CountyRecruitingGastroparesis Postoperative | Delayed Gastric Emptying Following ProcedureChina